Volume 15, Issue 4 (Jul-Aug 2021)                   mljgoums 2021, 15(4): 1-5 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Azadi F, Rezanezhadi M, Bagheri H, Alhusseini L B, Joshaghani H R. Identification of Mycobacterium tuberculosis and Rifampin Resistance in Pulmonary and Extra-pulmonary Clinical Specimens Using the Gene Xpert MTB/RIF Assay. mljgoums. 2021; 15 (4) :1-5
URL: http://mlj.goums.ac.ir/article-1-1314-en.html
1- Laboratory Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Master of microbiology, Kavosh Medical Laboratory, Research and Development unit, Gorgan, Iran
3- Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Golestan, Iran
4- Department of ecology, College of science, kufa university, kufa, najaf, Iraq
5- Laboratory Research Center, Golestan University of Medical Sciences, Gorgan, Iran , hr_joshaghani@yahoo.com
Abstract:   (328 Views)
Background and objectives: Tuberculosis (TB) is a serious public health problem and a significant diagnostic and therapeutic challenge worldwide. Molecular diagnostic techniques are crucial parts of the World Health Organization’s new tuberculosis control strategy. This study aims to identify Mycobacterium tuberculosis and rifampin resistance in pulmonary and extra-pulmonary clinical specimens using the Gene Xpert MTB/RIF assay.
Methods: The study was carried out on 220 specimens from pulmonary and extra-pulmonary TB patients that were sent to the Kavosh Laboratory in Gorgan (Iran) during 2018-20. The Gene Xpert MTB / RIF method was applied to detect M. tuberculosis and rifampin resistance.
Results: Of 220 specimens, 15 (6.81%) were found to be positive, four (26.6%) of which were related to pulmonary and 11(73.3%) to extra-pulmonary specimens. None of the positive samples was resitant to rifampin according to assay.
Conclusion: Our findings demonstrate that the Gene Xpert MTB/RIF is able to accurately detect M. tuberculosis in pulmonary and extra-pulmonary specimens. The accurate and early diagnosis of TB infection allows timely therapeutic intervention, which is beneficial not only for the patient but also for possible contacts.
Full-Text [PDF 619 kb]   (142 Downloads) |   |   Full-Text (HTML)  (140 Views)  
Research Article: Original Paper | Subject: bacteriology
Received: 2020/06/23 | Accepted: 2020/07/23 | Published: 2021/06/30 | ePublished: 2021/06/30

1. Moule MG, Cirillo JD. Mycobacterium tuberculosis Dissemination Plays a Critical Role in Pathogenesis. Frontiers in Cellular and Infection Microbiology. 2020; 10: 65. [View at Publisher] [DOI:10.3389/fcimb.2020.00065] [PubMed] [Google Scholar]
2. Pang Y, Shang Y, Lu J, Liang Q, Dong L, Li Y, et al. GeneXpert MTB/RIF assay in the diagnosis of urinary tuberculosis from urine specimens. Scientific reports. 2017; 7(1): 1-6. [View at Publisher] [DOI:10.1038/s41598-017-06517-0] [PubMed] [Google Scholar]
3. Habous M, Elimam MA, Kumar R, Deesi ZA. Evaluation of GeneXpert Mycobacterium tuberculosis/Rifampin for the detection of Mycobacterium tuberculosis complex and rifampicin resistance in nonrespiratory clinical specimens. International Journal of Mycobacteriology. 2019; 8(2): 132. [View at Publisher] [DOI] [PubMed] [Google Scholar]
4. Shi J, Dong W, Ma Y, Liang Q, Shang Y, et al. GeneXpert MTB/RIF outperforms mycobacterial culture in detecting mycobacterium tuberculosis from salivary sputum. BioMed Research International. 2018 ;2018. [View at Publisher] [DOI:10.1155/2018/1514381] [PubMed] [Google Scholar]
5. World Health Organization. Global status report on alcohol and health 2018. World Health Organization; 2019 Feb 14. [View at Publisher] [DOI] [PubMed] [Google Scholar]
6. Esmail H, Barry CE 3rd, Young DB, Wilkinson RJ. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci. 2014; 369(1645): 20130437. [DOI:10.1098/rstb.2013.0437] [PubMed] [Google Scholar]
7. Zürcher K, Ballif M, Kiertiburanakul S, Chenal H, Yotebieng M, et al. Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low‐and middle‐income countries: a multicohort study. Journal of the International AIDS Society. 2019; 22(9): e25392. [DOI] [PubMed] [Google Scholar]
8. Metcalf T, Soria J, Montano SM, Ticona E, Evans CA, Huaroto L, et al. Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis. PloS one. 2018; 13(6): e0198695. [DOI:10.1371/journal.pone.0198695] [PubMed] [Google Scholar]
9. Fahimzad SA, Ghasemi M, Shiva F, Ghadiri K, Navidinia M, Karimi A. Susceptibility Pattern of Bacille Calmette-Guerin Strains Against Pyrazinamide and Other Major Anti-Mycobacterial Drugs. Arch Pediatr. 2015 Jan;3(1):e17814. [View at Publisher] [DOI:10.5812/pedinfect.17814] [Google Scholar]
10. Kouassi KG, Riccardo A, Christian CD, André G, Férilaha C, Hortense SA, et al. Genotyping of mutations detected with GeneXpert. International Journal of Mycobacteriology. 2016; 5(2): 142-7. [DOI:10.1016/j.ijmyco.2016.01.001] [PubMed] [Google Scholar]
11. Mechal Y, Benaissa E, Benlahlou Y, Bssaibis F, Zegmout A, Chadli M, et al. Evaluation of GeneXpert MTB/RIF system performances in the diagnosis of extrapulmonary tuberculosis. BMC Infectious Diseases. 2019; 19(1): 1-8. [DOI:10.1186/s12879-019-4687-7] [PubMed] [Google Scholar]
12. Sadri H, Farahani A, Mohajeri P. Frequency of mutations associated with isoniazid-resistant in clinical Mycobacterium tuberculosis strains by low-cost and density (LCD) DNA microarrays. Annals of Tropical Medicine and Public Health. 2016 Sep 1;9(5):307. [DOI:10.4103/1755-6783.190166] [Google Scholar]
13. Atashi S, Izadi B, Jalilian S, Madani SH, Farahani A, Mohajeri P. Evaluation of GeneXpert MTB/RIF for determination of rifampicin resistance among new tuberculosis cases in west and northwest Iran. New microbes and new infections. 2017; 19: 117-20. [DOI:10.1016/j.nmni.2017.07.002] [PubMed] [Google Scholar]
14. Chen JH, She KK, Kwong TC, Wong OY, Siu GK, Leung CC, et al. Performance of the new automated Abbott RealTime MTB assay for rapid detection of Mycobacterium tuberculosis complex in respiratory specimens. European journal of clinical microbiology & infectious diseases. 2015; 34(9): 1827-32. [DOI:10.1007/s10096-015-2419-5] [PubMed] [Google Scholar]
15. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. European Respiratory Journal. 2013 Sep 1;42(3):708-20. [View at Publisher] [DOI:10.1183/09031936.00147912] [PubMed] [Google Scholar]
16. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB. World Health Organization; 2013. [PubMed] [Google Scholar]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2007 All Rights Reserved | Medical Laboratory Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.